On the other hand, hormone blocking therapies are very valuable to treat hormone responsive tumors, such as prostate and breast cancers, suggesting that withanolides that block hormone receptors may be a very useful tool for the treatment of hormone-sensitive tumors [76,77]. Here, NR4A1 is linked to breast carcinoma.